TY  - JOUR
AU  - de Miguel-Perez, Diego
AU  - Russo, Alessandro
AU  - Arrieta, Oscar
AU  - Ak, Murat
AU  - Barron, Feliciano
AU  - Gunasekaran, Muthukumar
AU  - Mamindla, Priyadarshini
AU  - Lara-Mejia, Luis
AU  - Peterson, Christine B
AU  - Er, Mehmet E
AU  - Peddagangireddy, Vishal
AU  - Buemi, Francesco
AU  - Cooper, Brandon
AU  - Manca, Paolo
AU  - Lapidus, Rena G
AU  - Hsia, Ru-Ching
AU  - Cardona, Andres F
AU  - Naing, Aung
AU  - Kaushal, Sunjay
AU  - Hirsch, Fred R
AU  - Mack, Philip C
AU  - Serrano, Maria Jose
AU  - Adamo, Vincenzo
AU  - Colen, Rivka R
AU  - Rolfo, Christian
PY  - 2022
DO  - 10.1186/s13046-022-02379-1
UR  - http://hdl.handle.net/10668/20349
T2  - Journal of experimental & clinical cancer research : CR
AB  - Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the...
LA  - en
KW  - Biomarkers
KW  - Extracellular vesicles
KW  - Immunotherapy
KW  - NSCLC
KW  - PD-L1
KW  - B7-H1 Antigen
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Extracellular Vesicles
KW  - Humans
KW  - Immune Checkpoint Inhibitors
KW  - Lung Neoplasms
KW  - Prospective Studies
KW  - Retrospective Studies
TI  - Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer.
TY  - research article
VL  - 41
ER  -